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Abstract
Background: Reproductive age may be a risk factor for vascular disease. Anti-Müllerian hormone (AMH) is produced
by viable ovarian follicles and reflects reproductive age. We examined whether AMH concentrations were associated
with markers of subclinical cardiovascular disease (CVD) and kidney disease among women with type 1 diabetes.
Methods: We performed a cross-sectional analysis of the Epidemiology of Diabetes Interventions and Complications
Study. Participants included women with type 1 diabetes and ≥1 AMH measurement (n = 390). In multivariable
regression models which adjusted for repeated measures, we examined the associations between AMH with CVD risk
factors, estimated glomerular filtration rate, and albumin excretion ratio. We also examined whether initial AMH
concentrations were associated with the presence of any coronary artery calcification (CAC) or carotid intima media
thickness (cIMT).
Results: After adjustment for age, AMH was not associated with waist circumference, blood pressure, lipid profiles, or
renal function. Higher initial AMH concentrations had borderline but non-significant associations with the presence of
CAC after adjustment for age (odds ratio [OR] 1.08, 95% confidence interval [CI] 1.00, 1.16) which were minimally
altered by addition of other CVD risk factors, although women in the 3rd quartile of AMH had lower odds of CAC than
women in the lowest quartile (OR 0.40, 95% CI 0.17, 0.94). After adjustment for age, higher AMH was associated with
statistically significant but only slightly higher cIMT (0.005 mm, p = 0.0087) which was minimally altered by addition of
other CVD risk factors.
Conclusions: Among midlife women with type 1 diabetes, AMH has slight but significant associations with subclinical
measures of atherosclerosis. Future studies should examine whether these associations are clinically significant.
Trial registration: NCT00360815 and NCT00360893 Study Start Date April 1994.
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Background
Reproductive age, traditionally categorized as reproduct-
ive stage (i.e. premenopausal or postmenopausal) [1],
may be a risk factor for chronic diseases including
cardiovascular disease (CVD) and kidney disease apart
from chronologic age. For example, an early age (less
than 40 years) of menopause may increase risk of both
coronary disease and stroke [2], and early age at meno-
pause is also associated with end stage renal disease
among women with type 1 diabetes [3]. Presumably,
such associations are mediated through ovarian hor-
mone effects on the vascular endothelium, or conversely
through the impact of chronic conditions on ovarian
function [4], although the key hormones and exact mecha-
nisms of action are not known. A serum marker of repro-
ductive age is anti-Müllerian hormone (AMH), a dimeric
glycoprotein that is produced solely by functioning ovarian
follicles [5]. AMH is a member of the transforming growth
factor-beta superfamily, which encompass a broad group of
receptors with endothelial activity [6], and hypothetically
could affect vascular disease via these receptors. In addition,
AMH has relatively minimal variations within the menstrual
cycle and has recently been incorporated into the STRAW
(Stages of Reproductive Aging Workshop) staging system
for reproductive aging [1]. As women approach menopause,
concentrations of AMH decline to undetectable values [7].
Thus, AMH has been increasingly used to predict ovarian
reserve in healthy populations as well as in women experi-
encing assisted reproductive technology [8–11].
Cross-sectional studies suggest that lower AMH con-
centrations are independently associated with hyperten-
sive disorders of pregnancy [4] as well as higher blood
pressure [12, 13] and less favorable lipid concentrations
[13, 14]. We have previously reported that AMH was not
associated with hemoglobin A1c in the EDIC cohort [15].
Reports examining AMH and subclinical atherosclerosis
are few and conflict [6, 13, 16, 17]. To our knowledge, no
reports in women have examined whether AMH is associ-
ated with markers of renal function.
Women with type 1 diabetes have an increased risk of
CVD and kidney disease compared to women without
diabetes [18]. Whether reproductive age independently
increases risk for CVD in this high-risk population is
not known. The Diabetes Control and Complications
Trial (DCCT) was a randomized trial that enrolled par-
ticipants with type 1 diabetes in order to compare the
impact of intensive vs. conventional diabetes therapy
upon microvascular complications [19]. During the
follow-up Epidemiology of Diabetes Interventions and
Complications (EDIC) study, coronary artery calcifica-
tion (CAC) and serial measures of common cIMT were
assessed, as well as AMH and serial measures of CVD
risk factors. Thus, we were able to examine whether
AMH was associated with CVD risk factor profile and
measures of subclinical atherosclerosis among women
with type 1 diabetes. In addition, estimated glomerular
filtration rate (eGFR) and albumin excretion ratio (AER)
were evaluated serially throughout DCCT and EDIC,
and we were able to examine whether AMH was associ-
ated with these markers of renal disease. As previous re-
ports have noted a U-shaped relationship between AMH
and CVD risk factors [13], our hypotheses were that
extremes of AMH are associated with CVD risk factor
profile and measures of subclinical atherosclerosis and
renal disease among women with type 1 diabetes.
Methods
The DCCT and EDIC studies have been described in de-
tail (14). Briefly, the DCCT was a multicenter, random-
ized clinical trial designed to compare the impact of
intensive and conventional diabetes treatment on the de-
velopment and progression of early microvascular com-
plications of type 1 diabetes [20]. From 1983 to 1989,
1441 patients (including 680 women) were enrolled at
29 centers. The intensive treatment regimen was
designed to achieve glycemic control as close to the
non-diabetic range as possible using ≥3 daily insulin in-
jections or an insulin pump. Conventional treatment
consisted of 1–2 daily insulin injections without stipu-
lated target glucose concentrations. The DCCT included
a primary prevention cohort and a secondary interven-
tion cohort. The primary prevention cohort consisted of
726 subjects with no retinopathy, urinary albumin excre-
tion rate < 40 mg/24 h, and diabetes duration of 1–
5 years at DCCT baseline. The secondary intervention
cohort consisted of 715 subjects who had non-
proliferative retinopathy, urinary albumin excretion
rate ≤ 200 mg/24 h, and diabetes duration of 1–15 years.
Individuals were excluded if they had hypertension
(defined by systolic blood pressure [SBP] levels ≥140 or
diastolic blood pressure [DBP] levels ≥90 mmHg), were
taking any blood pressure or lipid-lowering medications,
or had a history of symptomatic ischemic heart disease
or symptomatic peripheral neuropathy. Of the 680
women in the original DCCT cohort, 657 were postpu-
bertal and premenopausal at DCCT baseline.
In 1994, 615 women from the original DCCT cohort
enrolled in the Epidemiology of Diabetes Interventions
and Complications (EDIC) study, designed to follow par-
ticipants for long-term micro and macrovascular compli-
cations. During EDIC, a standardized annual history and
physical examination included a standardized interview
regarding menstrual patterns or discontinuation of men-
ses, gynecologic surgeries, and use of exogenous sex hor-
mones [21]. This report focuses upon the relationship
between AMH, CVD risk factors, and markers of sub-
clinical atherosclerosis during EDIC for women who had
not undergone hysterectomy or oophorectomy by EDIC
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year 17 and also had initial serum AMH measures
assessed during EDIC years 1–4, prior to CAC measures
at EDIC year 8 (n = 349) and cIMT measures at EDIC
year 6 (n = 390) (Fig. 1). Since AMH is made only by
ovulating ovaries, it is undetectable after menopause,
and previous reports noted that AMH levels were
undetectable at 6 years prior to menopause [22]. We
desired to limit the number of undetectable values, and
so we measured AMH only prior to menopause. We also
desired to have at least 2 values per woman, as AMH
declines linearly prior to menopause. Therefore, for
women who were naturally menopausal at EDIC year 17,
AMH was assessed as close to EDIC baseline as possible
and also assessed 7 years prior to their final menstrual
period (n = 148). In a subset of these women who had
reached natural menopause by EDIC year 17 (n = 50),
AMH was measured every other year prior to
menopause to ensure that the declines in AMH were
linear over time. For women who were still premeno-
pausal at EDIC year 17, AMH was assessed as close to
EDIC baseline as possible and also assessed at EDIC year
10. The median number of AMH measurements per
woman was 2, with an interquartile ratio of 1–4, at an
average of 6.3 years apart.
Clinical and biochemical endpoints were obtained an-
nually by history, physical exam, and laboratory testing
[23]. Body mass index (BMI), waist circumference, insu-
lin dosage, SBP and DBP, and hemoglobin A1c (HbA1c)
were assessed at randomization and quarterly during
DCCT and annually in EDIC [24]. Lipid profiles and
urinary albumin excretion rates (AER)/glomerular filtra-
tion rates (GFR) were obtained on alternate years. Total
cholesterol, triglyceride, and high-density lipoprotein
cholesterol (HDL) concentrations were determined by
Fig. 1 Flow chart of study participants
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enzymatic methods, and low-density lipoprotein choles-
terol (LDL) was calculated using the Friedewald equa-
tion [25]. Medication use was assessed at each exam by
EDIC staff. Cigarette use was also self-reported and
smoking was defined as reporting any cigarette use
currently.
AMH assays were performed on previously stored
samples by the EDIC Central Biochemistry Laboratory
in Minneapolis, MN using ELISA (Beckman Coulter
DSL, Webster, TX second generation kit) with a quanti-
fication limit of 0.08 ng/ml [26], lower than reported for
earlier generation assays [27]. Inter-assay coefficients of
variation (CV) provided by the manufacturer were 8.0%
at 0.15 ng/ml, 4.8% at 0.85 ng/ml and 6.7% at 4.28 ng/ml
(mean = 6.5%); intra-assay CV is 4.6% at 0.14 ng/ml,
2.4% at 0.84 ng/ml and 3.3% at 4.41 ng/ml (mean = 4.0%).
In the EDIC Central Biochemistry Laboratory, coeffi-
cients of variation were 8.1% at a mean concentration of
3.3 ng/ml and 4.2% at a mean concentration of 8.3 ng/
ml. For values less than the 0.08 ng/ml limit of quantifi-
cation but above the lower limit of detection, SoftMax
Pro software (Sunnyvale, CA) was used to plot values, fit
a cubic regression curve, and create splines which were
then used to estimate AMH concentrations.
Carotid ultrasonography was performed at approxi-
mately 1, 6, and 12 years after the initiation of the EDIC
study [28]. Carotid IMT (mm) was assessed in a central
unit (Tufts University, Boston, MA) by a single reader.
Computed tomography of the heart was performed once
during approximately the 8th EDIC year of follow-up [28].
At that visit, participants were scanned twice over calibra-
tion phantoms of known calcium concentration with
scans read centrally by readers who were masked to sub-
ject identity and previous treatment assignment. The aver-
age coronary artery CAC Agatston score from the 2 scans
was used in the analysis. Presence of CAC was defined as
an Agatston score > 6.25 mm3, which represents a value
that is <1% likely to be attributable to interscan variability.
Statistical analysis
We compared the distribution of CVD risk factors at
EDIC baseline by quartile of the initial measure of AMH
for each woman using analysis of variance for continu-
ous variables and the chi-square test for categorical vari-
ables. Next, we examined whether AMH concentrations
were associated with concurrent CVD risk factor values
before and after adjustment for age. General linear
mixed models accounted for multiple AMH measures
and CVD risk factor measurements within each woman
using PROC MIXED. Models examining blood pressure
and renal function were additionally adjusted for anti-
hypertensive medication use (angiotensin converting en-
zyme inhibitors, angiotensin receptor blockers, beta
blockers) at the time of blood pressure measurement;
other models examined lipid concentrations adjusted for
lipid-lowering medication at the time of measurement.
AMH was also modelled as a quadratic term, but this
did not change the significance of the associations, so
models are presented that assume a linear relationship
between AMH and CVD risk factors.
We examined the relationship between continuous mea-
sures of AMH and presence of CAC using logistic regres-
sion models. Models used the initial AMH level during
EDIC years 1–4 the primary independent variable and
CAC >0 at EDIC year 8 as the dependent variable, un-
adjusted and adjusted for concurrent CVD risk factors
measured during the same year as the initial AMH value.
Due to prior studies suggesting non-linear relationships
between AMH and CVD risk factors as well as non-linear
relationships between AMH and CAC in unadjusted com-
parisons, we performed a sensitivity analysis that exam-
ined AMH in quartiles rather than as a continuous
variable. Similarly, we examined the relationship between
continuous measures of AMH and cIMT using linear re-
gression models with the initial AMH level during EDIC
years 1–4 as the primary independent variable and con-
tinuous cIMT measure as the dependent variable, un-
adjusted and adjusted for concurrent CVD risk factors
measured during the same year as the initial AMH value.
As these models examined only a single measure of
AMH, adjustment for repeated measurements within
women were not performed. All analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Characteristics of women at EDIC baseline by quartile of
AMH value at their initial AMH measurement are
shown in Table 1. Women in the lowest quartile of
AMH were the oldest and women in the highest quartile
of AMH were the youngest. Women in the lowest quar-
tile of AMH had higher BMI, waist circumference, SBP,
total cholesterol, LDL, and triglyceride concentrations
and had lower eGFR than women in other quartiles.
Duration of diabetes, cigarette use, OCP use, BMI, waist
circumference, DBP, and HDL did not vary significantly
by AMH quartile. Hypertension, use of hypertensive
medications, and use of lipid-lowering medications was
uncommon. The women in the lowest AMH quartile
had the highest prevalence of CAC at year 8 (Table 2),
followed by women in the highest AMH quartile,
women in quartile 2, and then women in quartile 3. Al-
though there was no relationship between quartile in
AMH and cIMT at year 1, women in the lowest quartile
of AMH had the highest cIMT at years 6 and year 12
followed by women in quartiles 2, 3, and 4.
Table 3 shows the associations between continuous
measures AMH and concurrent individual CVD risk fac-
tors before and after adjustment for age, medication use,
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and multiple AMH and risk factor observations per
woman. Such analyses account for the fact that when
there are multiple observations per woman, the resulting
values are correlated i.e. cluster. In these adjusted ana-
lyses, AMH values were not associated with any CVD
risk factors or measures of renal function. When AMH
was modeled as a quadratic term, these associations did
not change.
There were 349 women who had AMH measurements
during years 1–4 and CAC measurements at EDIC year
8. Table 4 shows the odds of having any CAC by AMH,
before and after adjustment for age and other CVD risk
factors. After adjustment for age, AMH had non-
significant borderline associations with any CAC which
was not altered after adjustment for covariates. In a sen-
sitivity analysis, and due to the U-shaped relationship
with prevalence of CAC in unadjusted analyses, we also
examined the relationship between AMH in quartiles
and the presence of any CAC. Compared to women in
the lowest quartile of AMH, women in the 3rd or
Table 2 Presence of coronary artery calcification (CAC) and diameter of common carotid intima media thickness (cIMT) by baseline
quartile of women’s initial AMH measurement
Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value
CAC > 0 (%)a 33.7% 17.2% 11.1% 20.5% 0.002
CIMT year 1 (mm)b
Mean ± SD 0.620 ± 0.095 0.584 ± 0.059 0.595 ± 0.075 0.595 ± 0.075
Median 0.613 0.576 0.579 0.601
Range (0.449–0.841) (0.474–0.755) (0.466–0.791) (0.441–0.750) 0.22
CIMT year 6 (mm)c
Mean ± SD 0.642 ± 0.104 0.609 ± 0.087 0.595 ± 0.086 0.596 ± 0.088
Median 0.618 0.595 0.588 0.589
Range (0.451–1.10) (0.432–0.927) (0.429–0.824) (0.413–0.928) 0.002
aWomen who had AMH measures years 1–4 and CAC measurements at year 8 (n = 349)
bWomen who had initial AMH measurements at EDIC year 1 and cIMT at year 1 (n = 172)
cWomen who had initial AMH measurements at EDIC years 1–4 and cIMT measurements at EDIC year 6 (n = 390)
Means ± standard deviations or percentages shown
Table 1 Participant characteristics at EDIC baseline by quartile of women’s initial AMH measurement (n = 390 women)
Range of AMH (ng/dl) Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value
<0.96 0.96–2.70 2.70–4.61 >4.61
n = 99 n = 97 n = 98 n = 97
Age (years) 40.6 ± 6.2 34.6 ± 6.5 32.6 ± 6.0 31.0 ± 5.6 <0.0001
Diabetes duration (years) 14.4 ± 5.0 13.9 ± 5.2 14.4 ± 5.5 13.8 ± 5.4 0.78
Current smoking (%) 26.6% 20.4% 14.7% 15.1% 0.13
Current oral contraceptive use (%) 9.6% 18.3% 17.9% 11.8% 0.23
Body mass index (kg/m2) 26.8 ± 4.7 25.1 ± 3.8 25.8 ± 3.9 25.7 ± 3.8 0.05
Waist circumference (cm) 80.9 ± 11.2 77.2 ± 7.6 77.4 ± 8.6 78.7 ± 8.8 0.02
Systolic blood pressure (mm Hg) 118.4 ± 13.0 113.2 ± 10.8 112.4 ± 11.2 111.7 ± 12.1 0.0005
Diastolic blood pressure (mm Hg) 73.9 ± 8.9 72.8 ± 9.0 71.5 ± 8.4 72.0 ± 9.9 0.27
Hypertensiona 10.6% 7.5% 10.5% 14.0% 0.57
Total cholesterol (mg/dl) 200.5 ± 37.6 174.4 ± 31.0 179.3 ± 30.7 189.1 ± 33.1 <0.0001
Low-density lipoprotein cholesterol (mg/dl) 123.5 ± 34.8 101.8 ± 26.2 106.1 ± 26.8 113.1 ± 26.7 <0.0001
High-density lipoprotein cholesterol (mg/dl) 59.6 ± 14.5 59.6 ± 13.6 59.7 ± 13.8 59.8 ± 14.7 0.99
Triglycerides (mg/dl) 86.5 ± 45.0 65.1 ± 28.1 66.9 ± 30.5 80.6 ± 43.4 0.0001
Lipid medication use (%) 1.1% 2.2% 0% 0% 0.29
Log albumin excretion ratio (mg/day) 2.3 ± 1.0 2.5 ± 1.1 2.2 ± 1.0 2.6 ± 1.1 0.02
Estimated glomerular filtration rate (mL/min/1.73 m2) 106.2 ± 11.9 114.4 ± 16.2 113.3 ± 12.5 116.7 ± 13.3 <0.0001
aHypertension defined as systolic blood pressure ≥ 140 OR diastolic blood pressure ≥ 90 OR anti-hypertensive medication use
Means ± standard deviations or percentages shown
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highest quartile of AMH had a slightly lower odds of
any CAC after adjustment for age (odds ratio 0.40, 95%
confidence interval [CI] 0.17, 0.94) which was similar in
models which adjusted for both age and systolic blood
pressure (OR 0.40, 95% CI 0.17, 0.94) and age and
hemoglobin A1c (OR 0.40, 0.17, 0.94) although attenu-
ated in models that examined age, total cholesterol, and
high-density cholesterol (OR 0.46, 95% CI 0.19, 1.13).
These results did not differ when treatment group was
added as a covariate (data not shown).
The association between AMH and cIMT at years 1
and 6 are shown in Table 5. For cIMT measured at year
1, AMH was not associated with cIMT at year 1 before
or after adjustment for age. For cIMT measured at year
6, AMH was associated with statistically significant
although only very slightly higher cIMT which was not
altered after adjustment for CVD risk factors. In a sensi-
tivity analysis, when we examined AMH in quartiles,
there was no association between quartile of AMH and
degree of cIMT at year 1 or degree of cIMT at year 6.
Quartile of AMH was not associated with change in
cIMT between EDIC years 1 to 6 (results not shown),
nor was quartile of AMH associated with change in
cIMT between EDIC years 6 to 12 (results not shown).
Discussion
Women with type 1 diabetes have a higher prevalence of
reproductive disorders compared to women without dia-
betes, including irregular menses [29], subfertility [30],
and possibly polycystic ovary syndrome [31]. In addition,
women with type 1 diabetes are at greater risk for CVD
and renal disease than women without diabetes [18].
Thus, among women with type 1 diabetes, it plausible
that reproductive dysfunction could play a role in risk of
CVD and/or renal disease. AMH is increasingly used in
the diagnosis and management of reproductive disorders
and for reproductive staging [9]. In this cohort of
women with type 1 diabetes, AMH was not associated
with CVD risk factors after adjustment of age. After ad-
justment for age, there were associations between AMH
and CAC as well as between AMH and cIMT, although
the associations, when present, were slight and of
unclear clinical significance. AMH was associated with
significantly although minimally higher cIMT. Women
who had intermediate AMH concentrations, i.e. AMH
concentrations that were neither in the lowest nor the
highest quartile, had the lowest odds of CAC compared
to women in the lowest quartile of AMH.
Previous studies have suggested that AMH, a proxy
for reproductive age, might correlate with CVD risk fac-
tors independent of chronologic age. Only one report
has examined women with type 1 diabetes. In another
cohort of 150 premenopausal women with type 1 dia-
betes, higher concentrations of AMH were associated
with lower levels of SBP before and after adjustment for
age [13]. There was a U-shaped relationship between
AMH and HDL, where extremes of HDL were associ-
ated with low AMH concentrations. As with the current
report as well as our previous report examining HbA1c
and AMH [15], there was no significant correlation be-
tween AMH and DBP, AMH and LDL, or between
AMH and other diabetes characteristics including
Table 3 Associations between AMH (ng/dl) and levels of concurrent cardiovascular disease risk factors and renal function (n = 390
women with n = 781 observations)
Unadjusted Adjusted for age and medication usea
Systolic blood pressure (mm Hg) −0.32 (−0.60, −0.03) 0.005 (−0.29, 0.30)
Diastolic blood pressure (mm Hg) −0.01 (−0.21, 0.18) 0.11 (−0.10, 0.31)
Total cholesterol (mg/dl) −0.21 (−0.95, 0.53) −0.02 (−0.81, 0.77)
Low-density lipoprotein cholesterol (mg/dL) 0.02 (−0.63, 0.66) 0.02 (−0.66, 0.71)
High-density lipoprotein cholesterol (mg/dL) −0.14 (−0.44, 0.16) −0.05 (−0.37, 0.28)
Triglycerides (mg/dL) −0.25 (−1.22, 0.73) −0.10 (−1.16, 0.85)
Log albumin excretion ratio (mg/day) 0.02 (−0.003, 0.04) 0.01 (−0.01, 0.04)
Estimated glomerular filtration rate (mL/min/1.73 m2) 0.57 (0.25, 0.88) 0.02 (−0.29, 0.34)
Waist circumference (cm) −0.11 (−0.34, 0.12) −0.05 (−0.29, 0.20)
aAntihypertensive medication use for systolic and diastolic blood pressure, log AER, eGFR, and lipid-lowering medication use for total cholesterol, LDL, HDL, and
triglycerides. Age was the only adjustment made in the waist circumference model
Beta-coefficients and 95% confidence intervals shown from repeated measures regression models. Each beta-coefficient is per 1 ng/dl increment in AMH
Table 4 Association between initial measurement of AMH (ng/dl) during years 1–4 and CAC at year 8 before and after adjustment
for concurrent CVD risk factors (n = 349 women)
Unadjusted Adjusted for age Adjusted for age and SBP Adjusted for age, total cholesterol, and HDL Adjusted for age and A1c
AMH 1.01 (0.94–1.08) 1.08 (1.00–1.16) 1.08 (1.00–1.16) 1.08 (1.00–1.17) 1.08 (1.00–1.16)
Odds ratios and 95% confidence intervals shown
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diabetes duration, HbA1c, or BMI after adjustment for
age. We may not have found an association between
AMH and SBP due to differences between the study
populations. Although both studies performed AMH
and CVD risk factor measurements at similar ages,
EDIC did not exclude women with histories of irregular
menses, and it is possible that the relationship between
AMH and SBP differs among regularly cycling women.
We also adjusted for the use of anti-hypertensive medi-
cations, although this should have accentuated any exist-
ing associations between AMH and blood pressure. We
were also able to examine multiple AMH measurements
and CVD risk factor measurements within each woman
over time in a larger population.
Studies of AMH and CVD risk factors in populations
without diabetes conflict, although the associations be-
tween AMH and CVD risk factors, when documented,
have been modest. Reports in populations without dia-
betes have noted that AMH concentrations were not
cross-sectionally associated with blood pressure or lipid
profiles after adjustment for age and BMI [12, 32]. Teh-
rani et al. reported that women in the lowest quartile of
AMH eventually had slightly greater increases in total
cholesterol and LDL over a decade compared to women
in other quartiles [14]. However, adjustment for medica-
tion use was not noted, and the increases were slight,
the equivalent of 0.39 mg/dl per year, and adjustment
for age was performed by transforming actual AMH
levels into age-specific AMH levels, which might have
minimized the impact of age-adjustment. AMH was not
associated with progression in other risk factors; to our
knowledge, previous reports have not examined whether
AMH is associated with renal function.
Whether AMH could subsequently increase risk of
atherosclerosis via CVD risk factors or through an inde-
pendent pathway has not been well-studied. One report
in macaques (n = 66) suggested that AMH was associ-
ated with atherosclerotic plaque size [16]. Macaques in
the lowest tertile of AMH had greater plaque area than
macaques in the highest tertile. Similarly, Looby et al.
[17] noted that in a cohort consisting of HIV positive
and negative women, postmenopausal women had
higher prevalence of coronary plaque vs. perimenopausal
women vs. premenopausal women. AMH concentrations
were undetectable in the first two groups and detectable
in the last group. Other adjustments were not
performed, so the association may have been due to
other factors characterizing the menopausal transition.
Our report suggests that if AMH and odds of CAC are
associated, the relationship is not linear. Women in the
highest quartile of AMH may have similar risk of CAC
compared to women in the lowest quartile of AMH.
While explanations are speculative, it is possible that ele-
vated values of AMH correspond with other disorders,
such as polycystic ovary syndrome, which increase the
risk of CVD, and women with low values of AMH have
minimal ovarian reserve, which may also increase the
risk of CVD. Although mechanisms are speculative,
AMH has been linked with molecules with endothelial
activity, including vascular endothelial growth factor
(VEGF) [33]. VEGF regulates angiogenesis, and extremes
of VEGF confer decreased CVD risk [34]. Administra-
tion of VEGF has been demonstrated to stimulate AMH
receptor 2 expression, which in turn can increase AMH
binding in animal models [33]. Thus, AMH may be a
marker for angiogenesis dysregulation. Alternatively,
higher concentrations of inflammatory and endothelial
dysfunction markers among lymphoma patients includ-
ing interleukin 6 are significantly correlated with de-
creased AMH concentrations [35] as well as CVD risk
[36], suggesting that AMH may also be linked with CVD
through this pathway.
The two studies examining the relationship between
AMH and cIMT conflict. Among women with type 1
diabetes, AMH and cIMT and between AMH and other
measures of vascular flow were not related [13]. In a
population of women without diabetes [6], Figueroa-
Vega et al. lower AMH concentrations were strongly as-
sociated with thicker cIMT in 60 postmenopausal
women. In that report, we note that the majority of post-
menopausal women in this report had detectable and
even elevated concentrations of AMH exceeding 5 ng/dl,
Table 5 Associations between initial AMH (ng/dl) during years 1–4 and cIMT (mm) before and after adjustment for concurrent CVD
risk factors
Unadjusted Adjusted for age Adjusted for age and SBP Adjusted for age, total cholesterol, and HDL Adjusted for age and A1c
Models for year 1 cIMTa
AMH 0.00009 ± 0.002 0.002 ± 0.002 0.002 ± 0.002 0.002 ± 0.002 0.002 ± 0.002
p-value 0.95 0.11 0.10 0.22 0.13
Models for year 6 cIMTb
AMH 0.00008 ± 0.002 0.005 ± 0.002 0.005 ± 0.002 0.004 ± 0.002 0.004 ± 0.002
p-value 0.66 0.0087 0.008 0.019 0.014
aWomen who had AMH measurement at year 1 and cIMT measurements at EDIC year 1 (n = 172)
bWomen who had AMH measurement at year 1 and cIMT measurements at EDIC year 6 (n = 390)
Least square means and standard errors shown
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despite having undergone natural menopause an average
of 5 years before enrollment and use of an AMH assay
with a high detection limit (0.375 ng/ml), contrary to
previous reports suggesting that AMH declines to un-
detectable concentrations before the final menstrual
period [7, 8, 14, 37, 38]. We found that that higher con-
centrations of AMH were associated with slightly thicker
cIMT even after adjustment for covariates, although the
magnitude of the association was so slight as to render
clinical significance questionable.
Strengths of this report include its well-phenotyped
population of women with type 1 diabetes, enabling
examination of AMH with CVD risk factors as well as
CAC, cIMT, and renal function. We were able to assess
whether AMH was assessed with progression in cIMT as
well as single measures of cIMT. As our report included
women with type 1 diabetes, our results may not extend
to women without diabetes, who are at lower CVD risk.
We have previously reported that type 1 diabetes is asso-
ciated with lower AMH concentrations [39], and thus
diabetes may have modified the relationship between
AMH and CVD risk factor severity and between AMH
and atherosclerosis. Women in EDIC represent a cohort
of a randomized trial population and experienced excel-
lent glycemic control, and thus may not represent a
more generalized population of persons with type 1 dia-
betes. It is possible that ovarian reserve may have stron-
ger associations with subclinical atherosclerosis in a
population with a higher severity of disease; despite their
increased CVD risk from type 1 diabetes, women were
in their forties at the time of their CAC and cIMT as-
sessment, and the burden of disease was low. Similarly,
end-stage renal disease was uncommon in the EDIC co-
hort [40], and it is possible that the relationship between
AMH and renal disease would have been more pro-
nounced in a population with a higher incidence of dis-
ease. Finally, we note that due to our sampling strategy
of AMH measures prior to menopause, our power was
limited to detect relationships between lower concentra-
tions of AMH with greater burden of subclinical athero-
sclerosis or adverse risk factors.
Conclusions
Among women with type 1 diabetes, AMH has minimal
associations with CVD risk factors apart from chrono-
logic age, but AMH may have a non-linear relationship
with CAC and associations with cIMT. Future investiga-
tions should replicate these findings between AMH, par-
ticular in larger populations without diabetes. The
clinical significance of these associations is not known
and should be corroborated with investigations of out-
comes. The role of reproductive stage in CVD risk has
been controversial [41]. Reproductive stage is also
strongly associated with other end-organ complications,
including bone disease [42] and urologic conditions such
vaginal atrophy [43], and investigation of the role of
ovarian reserve in these complications should also be
conducted. Future investigations should also explore
whether the reproductive abnormalities experienced by
women with type 1 diabetes are CVD risk factors apart
from ovarian markers such as AMH.
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